mRNA manufacturing.

An mRNA lot is made from a sequence-defined DNA template, an enzymatic reaction, a series of purification pools and a set of lipid lots, brought together in a nanoparticle formulation step, sterile-filtered, filled and held cold. The manufacturing record has to show how a specific sequence became a specific formulated and filled lot, and it has to answer that question in both directions: from a template, lipid or filter finding forward to the vials it reached, and from a vial back to everything that made it.

Seal keeps the nucleic-acid and lipid lineages as controlled records that meet at formulation. IVT, purification, fill and cold-chain evidence attach to the containers they concern, and platform, product, site and batch remain separate, versioned layers.

Why teams choose Seal for mRNA manufacturing

The speed of an mRNA platform is also its risk: sequences, sites and configurations change faster than paper records and systems validated as fixed configurations can follow, and when “platform process” stands in for the version that ran, a deviation’s scope becomes an estimate. Each batch in Seal records the exact template, materials, device program and conditions it used, and a platform or product update shows the products and sites it affects before it is approved. Containment follows the genealogy, and release review starts from exceptions against a record that already reconstructs sequence to vial.

1Separate the platform from the product and the batch.

The approved product definition connects the encoded sequence, construct and template design, modifications, cap strategy, poly(A) approach, formulation, presentation, methods and specification. Effectivity is explicit: a sequence, template, raw-material, process, lipid, method or presentation change identifies the affected master records, inventory, validation, stability and regulatory commitments before use.

Seal keeps four layers. The platform defines reusable unit operations, material functions, equipment requirements and analytical concepts. The product applies the sequence, formulation, specifications and stability. The site resolves rooms, equipment, automation tags, local materials and procedures. The batch records what actually happened. A platform update shows the products and sites it affects without changing an active batch, and a product-specific limit can specialise a reusable method without duplicating the process. Tech transfer can then reuse qualified knowledge without assuming every product or facility is identical.

2Trace the template and critical materials into every reaction.

The DNA template is part of the drug record. Its construct version, manufacture, linearisation, purification, testing, storage, container and use authorisation stay linked, and Seal traces the exact template lot and container into every IVT reaction. A finding about sequence identity, residuals, integrity or storage traces forward to mRNA pools, formulated bulk, filled units and released lots.

Nucleotides, cap reagents, enzymes, buffers, filters, resins, lipids, solvents and excipients carry approved specifications, suppliers, lots, storage and preparation. Material attributes can influence yield, integrity, impurities, encapsulation and stability, so Seal keeps supplier and lot context in process and trend evidence rather than reducing every material to a part number and an expiry date.

3Record IVT and purification with their pools and clocks.

The electronic batch record defines reaction setup, additions, order, concentrations, temperature, time, mixing, sampling, holds and exception paths; actual lots, equipment, values, alarms and signatures accumulate during execution. Controllers and historians can remain authoritative for high-frequency data while Seal places the critical events and source references against the reaction, phase and batch. Missing or late data stays visibly incomplete and follows a defined recovery path.

DNA removal, chromatography, tangential-flow filtration, concentration and diafiltration transform the IVT material through intermediate pools. Every split, transfer, pool, filtrate, retentate, sample and discard records its source and destination containers, quantities, time, equipment, membrane or column and yield.

Defined events start hold clocks, and storage, transfer, freeze, thaw and sampling update each container’s exposure. Combining pools does not erase their history; the destination inherits the relevant exposure of its sources, and an excursion identifies the exact pool and downstream population. An in-process result may allow continuation, dilution, concentration or hold under approved ranges and decision tables. Seal records the data, rule, selected action and authorisation, and anything outside approved logic opens an exception rather than becoming an operator comment.

4Join the two lineages at LNP formulation.

The mRNA bulk and the lipid mixture meet at formulation. Seal verifies both sources, their concentrations and ratios, the equipment, the single-use path, the mixer or device program, flow rates, temperatures, pressures, timing, dilution, buffer exchange and filtration. The formulation record answers which pool, which lipid lots, which device and program, and which actual conditions produced the bulk, with residual quantities, samples and losses reconciled around the operation.

Single-use assemblies are manufactured configurations. Bags, tubing, mixers, connectors, filters and sensors are defined with eligible component types and positions, and execution records actual lots, sterilisation state, integrity checks, use window and disposal. An assembly or filter concern identifies every contacted pool and lot.

Analytical panels follow the structure of the product: identity, concentration, integrity, capping, poly(A), residual DNA and enzyme, double-stranded RNA, encapsulation, lipid content, particle size, polydispersity, potency, sterility and endotoxin, as the product requires. Each sample links to its source pool, stage, container, method, specification, instrument acquisition, calculation, review and any OOS or invalid state.

5Carry the lineage through fill and the cold chain.

Bioburden, sterilising-filter identity, integrity evidence, bulk hold, filling line, environmental state, interventions, container-closure components, inspection and reconciliation link finished units to the formulated bulk. EU GMP expects a sterilised filter assembly to be integrity tested before use where practicable and after use.¹ Seal connects the configured evidence; the sponsor determines the applicable scientific and regulatory strategy.

Storage location, probes, alarm events, transfers, shipments, freeze-thaw cycles and excursions stay attached to the physical container population. An excursion assessment starts with the affected interval and containers and sees prior exposure, stability support and distributed lots rather than a standalone temperature report.

Scheduling considers template and lipid availability, assemblies, suites, qualified people, hold windows, QC capacity, fill slots and freezer capacity. A campaign groups planned batches while each keeps its own lot identity and product-contact history, and switching sequence triggers the applicable clearance, cleaning and changeover. Parallel trains keep equipment and assembly identity for each batch, so yield and quality can be compared by line while the approved process determines which populations are equivalent.

6Release from a record that already reconstructs sequence to vial.

A material discrepancy, reaction excursion, low yield, unexpected impurity, filter failure, environmental event, OOS result or cold-chain excursion opens with the batch, phase, sources, equipment, samples and containers attached. Containment traverses the genealogy. Investigation and CAPA stay linked to the original evidence, and any reprocessing requires quality-unit review and approval and creates new execution with its own identity.²

The disposition view combines template and material lineage, IVT and purification execution, formulation, assemblies, process data, holds, results, aseptic evidence, deviations, reconciliation and approvals. Review by exception brings corrections, alarms, out-of-range values, missing data and open events forward while keeping the complete record available.

7Prove one sequence-to-vial lineage.

Trace one product version through template, materials, IVT, purification pools, holds, formulation, assemblies, process data, QC, sterile filtration and fill, cold storage, a deviation and disposition. Include a wrong material scan, a missing historian interval, a low-yield intermediate, a formulation adjustment, a filter-integrity concern, an OOS result and a temperature excursion.

The system is ready when each issue identifies the exact downstream population and the decision can be reconstructed from the record. Then extend the same layers to the next sequence or site.